Drug Trial Radar · NCT04587479
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Nov 23, 2020
Primary completion
Oct 31, 2024
Study completion Oct 31, 2024
Sponsor
- Lead sponsor
- Jacobio Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, first-in-human, open-label study of JAB-8263 to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT. 30 subjects with advanced solid tumor will be enrolled.
Conditions
- Solid Tumors, Adult
Interventions
JAB-8263Drug
Variable dose, orally Q2D with 28 days each cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicitiesTime frame: Approximately 2.5 years
- Find Recommended Phase 2 Dose (RP2D) of JAB-8263Time frame: Approximately 2.5 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
SCRI HeatlthONE
Denver, Colorado
Florida Cancer Center, Lake Mary
Lake City, Florida
Tennessee Oncology Nashville
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.